10-K/A - Lantern Pharma Inc. (0001763950) (Filer)

Wed, Apr 30, 10:10 AM (19 days ago)

**Lantern Pharma Inc. (LTRN) 10-K/A Amendment Summary** **Company Overview:** Lantern Pharma Inc. (LTRN) is a biopharmaceutical company focused on developing precision therapeutics in oncology using AI and genomics. The amendment to the 10-K report primarily updates corporate governance, executive compensation, and related party transactions. **Key Financial Metrics:** - **Revenue and Net Income:** Not explicitly stated in the amendment. - **Operating Expenses:** Not explicitly stated in the amendment. - **Earnings Per Share (EPS):** Not explicitly stated in the amendment. **Strategic Overview:** - **Corporate Governance:** The amendment includes updates to Part III, Items 10 through 14, providing detailed information on directors, executive officers, and corporate governance. - **Executive Compensation:** Detailed compensation information for named executive officers, including salary, bonuses, and stock options. - **Related Party Transactions:** Disclosure of transactions with related parties, including the purchase of shares from Bios Entities and collaboration with Actuate Therapeutics. **Future Outlook:** - **Strategic Initiatives:** Continued focus on AI and genomics in developing precision therapeutics. - **Market Position:** Evaluation of further collaborations with Actuate Therapeutics. **Risk Factors:** - **Competitive Environment:** Operating in a rapidly changing and competitive biopharmaceutical industry. - **Regulatory Risks:** Compliance with regulatory requirements and potential changes in regulations. **Financial Condition:** - **Liquidity and Capital Resources:** Not explicitly stated in the amendment. - **Debt Levels:** Not explicitly stated in the amendment. **Market Position Changes:** - **Stock Performance:** Not explicitly stated in the amendment. - **Market Capitalization:** Aggregate market value of voting and non-voting common equity held by non-affiliates is $44,285,965 as of the last business day of the most recently completed second fiscal quarter. **Changes Made in the Amendment:** - **Corporate Governance Updates:** Inclusion of previously omitted information in Part III, Items 10 through 14. - **Certifications:** New certifications by the principal executive officer and principal financial officer. - **No Financial Statement Changes:** The amendment does not include or amend any financial statements or disclosures related to Items 307 and 308 of Regulation S-K. **Conclusion:** The amendment provides comprehensive updates on corporate governance, executive compensation, and related party transactions, ensuring transparency and compliance with regulatory requirements. The company continues to focus on strategic initiatives in AI and genomics, navigating a competitive and rapidly changing market.